[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-respiratory-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-respiratory-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,73,103,127,151,185,209,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639712","light-based-immunomodulation-for-guarding-against-human-respiratory-tract-infections-100639712",false,"NCT07610967","Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections","LIGHT","Inclusion Criteria:\n\n* Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 years and older who work in the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.\n\nExclusion Criteria:\n\n* Unable to comfortably insert RD-X19 into the mouth and keep in place for 5 minutes\n* Plans for head, neck or mouth surgery during the study period\n* Plans for major dental procedures (ie implants, wisdom teeth extraction etc) during the study",true,"ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.",[27,28],"COVID-19 Respiratory Infection","Influenza","NOT_YET_RECRUITING","2026-05-20",{"date":32,"type":33},"2026-05-28","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2028-06",{"name":39,"class":40},"David Moss","FED",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100451918","cardiac-magnetic-resonance-tissue-characterization-in-covid-19-survivors-100451918","NCT05164744","Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors","Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors","Inclusion Criteria:\n\n* Emergency room presentation and\u002For hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea\u002Fvomiting, myalgias, fever, syncope\u002Fpresyncope.\n\nExclusion criteria:\n\n* Contraindication to CMR (i.e. non-compatible pacemaker\u002Fdefibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \\\u003C30 ml\u002Fmin\u002F1.73m2).\n* Inability to provide informed consent (e.g. cognitive impairment).\n* Unrelated condition (e.g. neoplasm) with life expectancy \\\u003C12 months prohibiting follow-up.\n* Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m2) will undergo non-contrast MRI but will not be excluded from this study.\n* Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.",{"count":49,"type":21},510,"OBSERVATIONAL","The purpose of this study is to test if visualizing the heart with cardiac MRI\u002Fecho will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.",[53,54,27,55,56,57,58],"COVID-19 Pneumonia","COVID-19","COVID-19 Acute Respiratory Distress Syndrome","COVID-19 Lower Respiratory Infection","COVID-19 Acute Bronchitis","Coronavirus Disease 2019",[60],"coronavirus disease 2019,","RECRUITING","2026-01-20",{"date":64,"type":33},"2026-01-22",{"date":66,"type":33},"2021-07-01",{"date":68,"type":21},"2026-07-30",{"name":70,"class":71},"Weill Medical College of Cornell University","OTHER",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":54,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100547003","passive-detection--sars-cov-2-covid-19-am-breathalyzer-protect-kiosk-for-operational-medicine-100547003","NCT06402318","Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine","A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.","Inclusion Criteria:\n\n* Asymptomatic and symptomatic individuals 18 years and older\n* Receiving standard COVID-19, Flu and\u002For RSV screening and testing at BAMC\n* Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened\n* Ability to understand consent\n\nExclusion Criteria:\n\n* Any individual under age of 18\n* Anyone unable to comply (or be assisted) with study procedures\n* Anyone not able to provide temperature thermal scan, and\u002For perform exhaled breath for approximately 8 seconds","89 Years",{"count":82,"type":21},100,"The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization.\n\nTo meet the objective and execute the deliverables for this program of effort, the A\\&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings.\n\nGoals:\n\n1. Optimization and operationalize the A\\&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR.\n2. Evaluate the passive sensing, breath capture system, built within the A\\&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.",[54,85,53,27,55],"SARS CoV 2 Virus",[87,88,89,90,91,92],"Breathalyzer","COVID-19 detection","Diagnostic Product","Pulmonary","PROTECT Kiosk","Passive Detection","2025-12-03",{"date":95,"type":33},"2025-12-10",{"date":97,"type":33},"2023-12-27",{"date":99,"type":21},"2026-03-30",{"name":101,"class":71},"The Geneva Foundation",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":102},"100448985","respiratory-virus-metagenomics-after-covid-19-100448985","NCT05126589","Respiratory Virus Metagenomics After COVID-19","Metagenomic Study on the Distributive Pattern of Respiratory Virus in the Community After the Emergence of COVID-19","Inclusion Criteria:\n\n* adults normally residing in Hong Kong\n* could communicate in English and\u002For Chinese\n* provision of consent\n\nExclusion Criteria:\n\n* individuals with mental illness\n* prisoners",{"count":111,"type":21},500,"The study aims to characterize the distributive pattern of viruses in upper airway and its relationship with influenza seasons, symptomatology and exposure setting. A total of 500 adults residing in Hong Kong would be recruited, who would complete a questionnaire and return self-collected nasal and throat swabs for metagenomic analyses.",[27],[115,116,117],"metagenomic","respiratory virus infections","exposure risk","2025-01-22",{"date":120,"type":33},"2025-01-24",{"date":122,"type":33},"2021-12-28",{"date":124,"type":21},"2027-01",{"name":126,"class":71},"Chinese University of Hong Kong",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":102},"100492199","phase-2-multicenter-randomized-double-blind-placebo-controlled-study-to-investigate-azvudine-in-symptomatic-adults-with-covid-19-at-increased-risk-of-progressing-to-severe-illness-100492199","NCT05689034","Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness","A Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adult Participants With COVID-19 Who Are at Increased Risk of Progressing to Severe Illness","Inclusion Criteria:\n\n* (1) An age of 18 years or over (inclusive); (2) Not more than five days since the development of COVID-19 symptoms, and positive for nucleic acid or antigen test for COVID-19 within five days before enrollment; (3) Presence of at least one symptom related to COVID-19 infection at the time of enrollment; (4) Agreement to practice effective birth control (for females of child-bearing potential); (5) Presence of at least one high risk factor for severe COVID-19 infection:\n\n  * Age ≥ 60 years;\n\n    * BMI\\>25；\n\n      * Fever (body temperature ≥ 38℃) for ≥ 3 days;\n\n        * Current smokers (still being smoking within 30 days before enrollment and have used at least 100 cigarettes up to date);\n\n          * Immunosuppressive diseases, including but not limited to: myelosuppression or organ transplantation or primary immunodeficiency disease; prolonged use of immunosuppressive agents (≥ 20 mg\u002Fd for at least 14 days in the case of prednisone within the last 30 days); biologic therapy (such as infliximab, etc.); use of immunomodulators (including but not limited to methotrexate, azathioprine, etc.); radiotherapy and\u002For chemotherapy for any malignancies within 90 days (for chest radiotherapy, this time interval should be more than 6 months);\n\n            * Chronic lung disease (such as asthma requiring intervention daily, bronchiectasis, COPD, pulmonary hypertension, OSAS, interstitial lung disease, etc.);\n\n              * Hypertension; ⑧ Cardiovascular diseases (previously diagnosed as myocardial infarction or stroke, TIA (transient ischemic attack), cardiac insufficiency, angina pectoris requiring nitrate therapy, CABG, post-PCI, post-carotid endarterectomy and aortic bypass surgery, etc.);\n\n                ⑨ Type 1 or type 2 diabetes;\n\n                ⑩ Neurodevelopmental abnormalities (such as cerebral palsy, Down's syndrome) or other genetic or metabolic syndromes and severe congenital malformations;\n\n                ⑪ Active tumors (excluding localized skin cancer);\n\n                ⑫ No vaccination against COVID-19\n\nExclusion Criteria:\n\n* (1) Known or suspected allergy to the components of Azvudine Tablets; (2) Patients diagnosed as severe or critical COVID-19 infection (Severe: 1. shortness of breath with RR ≥ 30 breaths\u002Fmin; 2. oxygen saturation ≤ 93% when inhaling air at rest; 3. partial pressure of arterial oxygen (PaO2) \u002F fraction of inspired oxygen (FiO2) ≤ 300 mmHg; 4. progressive worsening of clinical symptoms, and obvious lesion progression \\> 50% on lung images within 24 to 48 hours. Critical: 1. respiratory failure, requiring mechanical ventilation; 2. shock; 3. concomitant organ failure, requiring care in ICU); (3) Patients with severe liver disease (total bilirubin \\[TBIL\\] ≥ 2 × upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3 × ULN; (4) Patients with severe renal insufficiency (glomerular filtration rate ≤ 60 mL\u002Fmin\u002F1.73 m2) or currently on continuous renal replacement therapy, hemodialysis, and\u002For peritoneal dialysis; (5) Patients with malabsorption syndrome or any other condition compromising gastrointestinal absorption, or patients requiring parenteral nutrition or with difficulty in taking the investigational product orally; (6) Known HIV infection; (7) Presence of diabetic ketosis or hyperosmolar hyperglycemic state (HHS); (8) Total neutrophil count \\\u003C 750 cells\u002FL; (9) Pregnant or lactating women or those who plan to have a child during participation in this study and within six months after the end of this study; (10) Currently participating in another clinical trial or currently using another investigational product; (11) Presence of other active infections (must be etiologically confirmed) in addition to COVID-19 infection; (12) Presence of any comorbidities requiring hospitalization and\u002For a surgical procedure within 7 days prior to the start of this study or a comorbidity considered life-threatening within 30 days prior to the start of this study; (13) Patients who have received or are expected to receive convalescent plasma for COVID-19; (14) Previous treatment with anti-viral agents that have been proved to be effective against COVID-19, including but not limited to Nirmatrelvir\u002FRitonavir or Molnupiravir (this criterion does not apply to use of glucocorticoids for reasons other than COVID-19); (15) Other conditions that make it inappropriate for the participant to take part in this trial at the investigator's discretion.","120 Years",{"count":136,"type":21},1096,[138,139],"PHASE2","PHASE3","To investigate whether treatment with Azvudine reduces the risk of severe illness or death in patients who are at a potential risk of progressing to severe COVID-19 infection.",[27],"2024-11-21",{"date":144,"type":33},"2024-11-25",{"date":146,"type":33},"2023-04-19",{"date":148,"type":21},"2025-12-31",{"name":150,"class":71},"Peking Union Medical College Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":170,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100482474","trial-of-venovenous-ecmo-to-de-sedate-extubate-and-mobilise-in-hypoxic-respiratory-failure-100482474","NCT05562505","Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure","A Randomised Controlled Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure","REDEEM","Inclusion Criteria:\n\n1. Patients ≥18 to 65 years old\n2. Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support\n3. Mechanical ventilation of \\\u003C7 days\n4. Moderate to severe respiratory failure, as demonstrated by two P:F ratios \\\u003C150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio \\> 150mmHg are permitted between the two trial inclusion ABGs.\n5. Trial of proning (unless contraindicated)\n\nExclusion Criteria:\n\n1. The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)\n2. Cardiogenic cause of respiratory failure\n3. Chronic hypercapnic respiratory failure defined as PaCO2 \\> 60 mmHg in the outpatient setting\n4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP\u002FBIPAP used solely for sleep disordered breathing\n5. Confirmed diffuse alveolar haemorrhage from vasculitis\n6. Neurologic conditions, i.e. undergoing treatment for intracranial hypertension\n7. Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)\n8. Patient needing immediate VV ECMO (as per EOLIA criteria)\n9. The patient is moribund and deemed unlikely to survive past 24 hours (as determined by the clinical team)\n10. The patient is being transitioned to palliative care\n11. Contraindications to anticoagulation (e.g., active GI bleeding, bleeding predisposition, severe trauma)\n12. Previous hypersensitivity\u002Fanaphylactic reaction to heparin or heparin-induced thrombocytopenia\n13. Participation or Consent is declined, OR\n14. Unable to identify or Contact surrogate decision maker.","65 Years",{"count":161,"type":21},140,[24],"To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.",[165,166,167,27,168,169],"Mechanical Ventilation Complication","Hypoxemia","Acute Respiratory Distress Syndrome Due to COVID-19","Pneumonia","Extracorporeal Membrane Oxygenation",[171,172,169,173,174],"Intensive Care Unit","ECMO","Mechanical Ventilation","Early ECMO","2024-08-06",{"date":177,"type":33},"2024-08-09",{"date":179,"type":33},"2022-11-28",{"date":181,"type":21},"2027-01-31",{"name":183,"class":71},"Australian and New Zealand Intensive Care Research Centre",7,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":102},"100553796","evolution-of-respiratory-function-in-lung-transplant-patients-with-moderate-to-severe-covid-19-infection-100553796","NCT06490744","Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection","Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe SARS-Cov-2 Infection, Single-center Retrospective Study","Cov- EvoLuT","Inclusion Criteria:\n\n* Adult patient\n* Lung transplant patient (monopulmonary or bipulmonary)\n* Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022\n* Hospitalization at the University Hospitals of Strasbourg for COVID-19\n* Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg\n* Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes.\n\nExclusion Criteria:\n\n* Subject having expressed his opposition to the reuse of his data for scientific research purposes.",{"count":194,"type":21},75,"The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failures and deaths across the world. Certain factors have been identified as associated with a higher risk of developing a severe form and dying. Immunosuppression has been identified as a risk factor for progressing to a severe form.\n\nLung transplant patients were particularly vulnerable during this period, with a high frequency of respiratory compromise, sometimes progressing towards acute respiratory distress syndrome and, at a later stage, towards fibrotic forms. The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied. The various treatments implemented during the pandemic have rapidly evolved (immunotherapy, vaccination, convalescent plasma transfusion, etc.) which may have modulated this risk. The evolution of respiratory function may be linked to the respiratory infection itself, or to the severity of respiratory damage during the infection. It is therefore relevant to compare patients with a moderate form of COVID-19 (non-intubated patients) to patients with severe forms, requiring invasive ventilation in intensive care. The evolution of respiratory function after infection has not yet been studied.",[27],[198,53,27,199],"Covid-19","SARS-Cov-2","2024-07-04",{"date":202,"type":33},"2024-07-08",{"date":204,"type":33},"2023-09-04",{"date":206,"type":21},"2024-12-31",{"name":208,"class":71},"University Hospital, Strasbourg, France",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":233},"100550822","efficacy-and-safety-study-of-essential-oil-based-preparation-administered-to-covid-19-patients-100550822","NCT06452069","Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients","A Multicentre, Randomised, Prospective Study Investigating the Efficacy and Safety of an Essential Oil-Based Preparation Administered to Mild and Moderately Severe COVID-19 Positive Patients","Inclusion Criteria:\n\n* Patients must be between 18\\\u003CX\\\u003C 65 years of age.\n* The participant must be willing and able to give written informed consent. The volunteer must provide his\u002Fher consent on his or her behalf, a legally acceptable representative (i.e., an International Harmonization Council \\[ICH\\] and adopted by local law as appropriate can be used) must give informed consent on his\u002Fher behalf.\n* PCR test COVID-19 positive diagnosis and mild to moderate disease stage is required.\n* The participant must agree not to receive vaccines administered for COVID-19 during the study.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age,\n* Positive diagnosis of severe COVID-19 with symptoms of basic severity: patients with respiratory distress, signs of mental confusion and impaired consciousness that develop depending on the severity of the stage of the disease,\n* Patients on active antiviral therapy,\n* Patients with creatine clearance \\\u003C 30 ml\u002Fmin and renal impairment,\n* NYHA III-IV, Stage D heart failure patients requiring frequent hospitalization,\n* Uncontrolled coagulopathy,\n* Patients with advanced liver failure,\n* Patients with active infections such as hepatitis B, hepatitis C and HIV, diseases requiring systemic treatment,\n* Patients with active malignancy and known history of cancer,\n* Those who do not have sufficient psychic state to disrupt working rounds,\n* Active drug users,\n* Known hypersensitivity and allergic reaction to the components of the preparation,\n* Current participation in another interventional treatment study with an investigational agent,\n* Recent use of the investigational product within 28 days of the first dose of the investigational product use or presence of a research device during screening,\n* Pregnant or breastfeeding women,\n* Patients who did not give written informed consent.",{"count":217,"type":21},280,[24],"The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR. A computational simulation approach of the molecular interaction (binding) of the main components of essential oils exhibiting antiviral activity with known intracellular protein targets of SARS-CoV-2 (nsp5: Main Protease) was adopted as a rationale for this study. SARS-CoV-2, a single-stranded RNA virus, has four major structural proteins Spike (S), Membrane (M), Envelope glycoprotein (E) and Nucleocapsid (N) protein and non-structural proteins (nsp). These non-structural proteins, of which there are 16 in total in the genome of the virus, play key roles in the mechanisms of the virus life cycle, including replication, transcription, protein synthesis and modification of RNA. Main protease (Main protease, Mpro, 3CLpro), virus Since they are directly involved in the maturation of these nsp proteins, which have an important role in many mechanisms of the life cycle, they have been the target enzyme in the development of new antiviral drugs for the treatment of COVID-19. In this study, our main rationale is to investigate the effect of essential oils on nsp5: Main Protease enzyme activations.",[27,54],[222],"Essential Oil, antiviral, Main Protease, COVID 19","2024-06-11",{"date":225,"type":33},"2024-06-13",{"date":227,"type":21},"2024-09-15",{"date":229,"type":21},"2025-09-15",{"name":231,"class":232},"Biodex S.A","INDUSTRY",10,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":102},"100430633","dynamics-of-markers-of-infection-and-inflammation-in-hospitalized-coronavirus-disease-2019-covid-19-patients-100430633","NCT04887623","Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients","Dynamics of Nucleocapsid Antigen Serum Levels and Other Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients - a Pilot Study","Inclusion Criteria:\n\n* SARS CoV2 positive test within last 14 day\n* bilateral infiltrates on chest X.ray or CT\n* need for oxygen to keep pulse oximetry saturation above 92% or other respiratory support measures (HFNO, non-invasive ventilation or invasive ventilation)\n\nExclusion Criteria:\n\n* known history of intersticial lung disease\n* known history of congestive heart failure","90 Years",{"count":243,"type":21},30,"Patients requiring admission to the hospital due to a moderate and severe COVID-19 infection may differ in their ability to respond to viral infection and to eliminate viral load.\n\nSeveral comorbidities and interventions like antivirotic or antiinflammatory treatment may also modify expected patients response and decrease of viral load.\n\nIn this observational study, evolution of selected inflammatory markers, indicators of severity of infection and patient characteristics will be followed and recorded in hospitalized patients with COVID-19.",[27],[247,248,249,250],"Covid19","Interleukin 6","viremia","nucleocapsid antigen","2024-05-09",{"date":253,"type":33},"2024-05-10",{"date":255,"type":33},"2021-04-01",{"date":257,"type":21},"2026-08",{"name":259,"class":71},"University Hospital Hradec Kralove"]